Answers are grounded in this paper and cite their sources.
3 Background: Incidentally encountered lung nodules on chest radiographs (CXRs) are frequently overlooked in routine clinical practice. A Thai institutional study demonstrated that up to 79% of lung cancers visible in retrospect on CXRs were missed by both radiologists and clinicians (Chutivanidchayakul et al., Clin Imaging 2023). Even when AI systems flag suspicious nodules, clinician non-concordance remains a critical barrier. We implemented a three-step safety-net workflow integrating AI detection, systematic monitoring, and radiologist second-look review through a dedicated lung nodule clinic to close this diagnostic gap. Methods: Over 1 year, all CXRs obtained for any clinical indication at Phrapokklao Hospital and its spoke network in Chanthaburi, Thailand, were analyzed by qXR (Qure.ai) for lung nodule detection. The workflow comprised: (1) AI-flagged detection of actionable high-risk lung nodules (HLNMs), (2) centralized monitoring to capture all flagged cases regardless of treating physician response, and (3) radiologist second-look review to validate findings and refer confirmed cases for diagnostic CT and biopsy. Lung cancers were histologically confirmed and staged per AJCC 8th edition. Results: Of 107,238 CXRs processed, qXR identified 691 actionable HLNMs (0.64%). Through the safety-net pathway, 382 (55.3%) underwent diagnostic CT and 124 (32.5%) proceeded to biopsy. Forty-seven lung cancers were confirmed (1 per 2,282 CXRs), plus 2 non-lung metastatic cancers. Among 33 patients with complete staging: stage I (n=3), stage II (n=11), stage IIIA–C (n=9), and stage IV (n=10). Overall, 23/47 (48.9%) were early-stage (I–III). Conclusions: AI detection alone is insufficient when clinicians fail to act on flagged findings. Our three-step safety-net model effectively bridges the gap between AI identification and clinical action, capturing lung cancers that would otherwise be missed. Nearly half were early-stage, demonstrating meaningful diagnostic acceleration. This approach addresses an underrecognized failure point in AI-augmented workflows and offers a scalable model for reducing missed lung cancer in routine practice.
No takes yet. Share an insight, caveat, or question.
Wanchaijiraboon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: